Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
Clinical trial study of the therapeutic effect of Tenofovir antiviral drug in combination with Kaletra and Chloroquine diet in the treatment of Coronavirus patients in 2019 (COVID-19)
Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients
Clinical trial studyComparison of the therapeutic effectEffectiveness of Tenofovir antiviral drug in combination with Kaletra and Chloroquine dietbeside routine drug regime (standard of care) in the treatment of Coronavirus patients in 2019 (COVID-19) patients
مطالعه کارازمایی بالینی بررسی تاثیر درمانی داروی ضد ویروسی Tenofovir در کنار رژیم دارویی Kaletra و Chloroquine در درمان بیماران کرونا ویروس 2019 (COVID-19)
مطالعه کارازمایی بالینی بررسی تاثیر درمانی داروی ضد ویروسی Tenofovir درکنار رژیم دارویی روتین (standard of care) در درمان بیماران کرونا ویروس 2019 (COVID-19)
مطالعه کارازمایی بالینی بررسی تاثیر درمانی داروی ضد ویروسی Tenofovir در کناردرکنار رژیم دارویی Kaletra و Chloroquineروتین (standard of care) در درمان بیماران کرونا ویروس 2019 (COVID-19)
Clinical trial with control group, parallel group trial, double-blinded, phase 2 on 60 patients. Replacement randomization was used.
Clinical trial with control group, parallel group trial, open lable, phase 2 on 60 patients. Replacement randomization was used.
Clinical trial with control group, parallel group trial, double-blindedopen lable, phase 2 on 60 patients. Replacement randomization was used.
کارآزمایی بالینی دارای گروه کنترل، با گروه های موازی ، دو سویه کور ، تصادفی شده، فاز 2 بر روی 60 بیمار. برای تصادفی سازی از تصادفي سازي جايگزيني ( Replacement
(randomization استفاده شد.
کارآزمایی بالینی دارای گروه کنترل، با گروه های موازی ، open lable ، تصادفی شده، فاز 2 بر روی 60 بیمار. برای تصادفی سازی از تصادفي سازي جايگزيني ( Replacement
(randomization استفاده شد.
کارآزمایی بالینی دارای گروه کنترل، با گروه های موازی ، دو سویه کورopen lable ، تصادفی شده، فاز 2 بر روی 60 بیمار. برای تصادفی سازی از تصادفي سازي جايگزيني ( Replacement (randomization استفاده شد.
In both study groups (control and case), on the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg. In addition to the above drugs Alfamed Tenofovir, Case is given daily at 25 mg daily for 7 days.
In both study groups (control and case), on the first day, patients will receive routine drug regime (standard of care). In addition to the above drugs Alfamed Tenofovir, Case is given daily at 25 mg daily for 7 days.
In both study groups (control and case), on the first day, patients will receive chloroquine at a doseroutine drug regime (standard of 200 mg, and from the second day for six consecutive days they will receive Lopinavir / ritonavir (Kaletracare) at a dose of 400/100 mg. In addition to the above drugs Alfamed Tenofovir, Case is given daily at 25 mg daily for 7 days.
در هر دو گروه مطالعه (شاهد و مورد) در روز اول بیماران داروی کلروکین با دوز 200 mg دریافت می کنند و از روز دوم به مدت شش روز متوالی داروی Lopinavir/ritonavir) Kaletra ) با دوز 400/100 mg دزیافت خواهند کرد. به افراد گروه Case علاوه بر داروهای فوق داروی Tenofovir آلفامد، روزانه به میزان 25 mg، به مدت 7 روز داده می شود.
در هر دو گروه مطالعه (شاهد و مورد) در روز اول بیماران رژیم دارویی روتین را دریافت خواهند کرد. به افراد گروه Case علاوه بر داروهای فوق داروی Tenofovir آلفامد، روزانه به میزان 25 mg، به مدت 7 روز داده می شود.
در هر دو گروه مطالعه (شاهد و مورد) در روز اول بیماران داروی کلروکین با دوز 200 mgرژیم دارویی روتین را دریافت می کنند و از روز دوم به مدت شش روز متوالی داروی Lopinavir/ritonavir) Kaletra ) با دوز 400/100 mg دزیافت خواهند کرد. به افراد گروه Case علاوه بر داروهای فوق داروی Tenofovir آلفامد، روزانه به میزان 25 mg، به مدت 7 روز داده می شود.
Inclusion criteria: 1. People over 18 years of age. 2. Positive Real-time PCR test for SARS-CoV-2 virus positive after sampling (nasopharyngeal and oropharyngeal swab samples). 3. Pneumonic manifestations of the virus. In CT scans of the lungs, they should be clearly visible, with a 4% lower O2 Saturation of 93%
exclusion criteria: 1- History of renal failure, 2- Taking drugs that interfere with Tenofovir and 3- Patients who have been included in other clinical trial studies
Inclusion criteria: 1. People over 18 years of age. 2. Positive Real-time PCR test for SARS-CoV-2 virus positive after sampling (nasopharyngeal and oropharyngeal swab samples). 3. Pneumonic manifestations of the virus. In CT scans of the lungs, they should be clearly visible, with a 4% lower O2 Saturation of 93%
exclusion criteria: 1- History of renal failure, 2- Taking drugs that interfere with Tenofovir and 3- Patients who have been included in other clinical trial studies
Inclusion criteria: 1. People over 18 years of age. 2. Positive Real-time PCR test for SARS-CoV-2 virus positive after sampling (nasopharyngeal and oropharyngeal swab samples). 3. Pneumonic manifestations of the virus. In CT scans of the lungs, they should be clearly visible, with a 4% lower O2 Saturation of 93% exclusion criteria: 1- History of renal failure, 2- Taking drugs that interfere with Tenofovir and 3- Patients who have been included in other clinical trial studies
Case group: Get the Tenofovir + Kaletra + Chloroquine
Control group: Get the Kaletra + Chloroquine
Case group: Get the Tenofovir + standard of care
Control group: Get the standard of care
Case group: Get the Tenofovir + Kaletra + Chloroquinestandard of care Control group: Get the Kaletra + Chloroquinestandard of care
گروه هدف:دریافت درمان دارویی Tenofovir + Kaletra + Chloroquine
گروه کنترل: دریافت رژیم روتین دارویی Kaletra + Chloroquine
گروه هدف:دریافت درمان دارویی Tenofovir درکنار رژیم دارویی روتین (standard of care)
گروه کنترل: دریافت رژیم دارویی روتین (standard of care)
گروه هدف:دریافت درمان دارویی Tenofovir + Kaletra + Chloroquineدرکنار رژیم دارویی روتین (standard of care) گروه کنترل: دریافت رژیم دارویی روتین دارویی Kaletra + Chloroquine(standard of care)
General information
Single blinded
Not blinded
singlnotbl
1
1
empty
The standard of care regimens approved by the Ministry of Health differed from the time of the trial at the time of registration. Also, the study method was changed from a double blinding study to an open-label study.
The standard of care regimens approved by the Ministry of Health differed from the time of the trial at the time of registration. Also, the study method was changed from a double blinding study to an open-label study.
empty
رژیم های درمانی استاندارد مورد تایید وزارت بهداشت در زمان ثبت ترایال نسبت به زمان انجام ترایال متفاوت بودند. همچنین روش اجرای مطالعه از دو سو کور به مطالعه open label تغییر یافت.
رژیم های درمانی استاندارد مورد تایید وزارت بهداشت در زمان ثبت ترایال نسبت به زمان انجام ترایال متفاوت بودند. همچنین روش اجرای مطالعه از دو سو کور به مطالعه open label تغییر یافت.
Clinical trial study on the therapeutic effect of Tenofovir besides Kaletra and Chloroquinein in patients with Coronavirus disease 2019 (COVID-19)
Clinical trial study on the therapeutic effect of Tenofovir besides routine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)
Clinical trial study on the therapeutic effect of Tenofovir besides Kaletra and Chloroquineinroutine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)
مطالعه کارازمایی بالینی بررسی تاثیر درمانی داروی ضد ویروسی Tenofovir در کنار رژیم دارویی Kaletra و Chloroquine در درمان بیماران کرونا ویروس 2019 (COVID-19)
مطالعه کارازمایی بالینی بررسی تاثیر درمانی داروی ضد ویروسی Tenofovir درکنار رژیم دارویی روتین (standard of care) در درمان بیماران کرونا ویروس 2019 (COVID-19)
مطالعه کارازمایی بالینی بررسی تاثیر درمانی داروی ضد ویروسی Tenofovir در کناردرکنار رژیم دارویی Kaletra و Chloroquineروتین (standard of care) در درمان بیماران کرونا ویروس 2019 (COVID-19)
Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquine) in COVID-19 patients
Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients
Comparison of the Effectiveness of Tenofovir antiviral drug beside (Kaletra and Chloroquine) with routine drug regime (Kaletra and Chloroquinestandard of care) in COVID-19 patients
مقایسه اثر بخشی داروی ضد ویروسی Tenofovir درکنار (Kaletra و Chloroquine) با رژیم دارویی روتین (Kaletra و Chloroquine) در درمان بیماران مبتلا به COVID-19
مقایسه اثر بخشی داروی ضد ویروسی Tenofovir درکنار رژیم دارویی روتین (standard of care) در درمان بیماران مبتلا به COVID-19
مقایسه اثر بخشی داروی ضد ویروسی Tenofovir درکنار (Kaletra و Chloroquine) با رژیم دارویی روتین (Kaletra و Chloroquinestandard of care) در درمان بیماران مبتلا به COVID-19
To reduce bias , the single-blind method is used, which can be used to ensure that the outcome is measured objectively. In this method, the test the participant does not know which of the two groups of control or test belongs.
To reduce bias , the single-blind method is used, which can be used to ensure that the outcome is measured objectively. In this method, the test the participant does not know which of the two groups of control or test belongs.
برای کاهش سوگیری یا تورشهای مربوط به مداخله و ارزیابی پیامدها، از روش کور بودن یا پوشیده سازی یک سوکور single blind پیروی می شود، با این روش می توان از سنجش پیامد بصورت عینی، مطمئن شد. در این روش، کارازمایی به نحوی برنامه ریزی می شود که شرکت کننده متوجه نمی شود به کدام یک از دو گروه شاهد یا مورد آزمایش تعلق دارد.
برای کاهش سوگیری یا تورشهای مربوط به مداخله و ارزیابی پیامدها، از روش کور بودن یا پوشیده سازی یک سوکور single blind پیروی می شود، با این روش می توان از سنجش پیامد بصورت عینی، مطمئن شد. در این روش، کارازمایی به نحوی برنامه ریزی می شود که شرکت کننده متوجه نمی شود به کدام یک از دو گروه شاهد یا مورد آزمایش تعلق دارد.
Intervention groups
#1
Intervention group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg daily for 7 days.
Intervention group: On the first day, patients will receive routine drug regime (standard of care) daily for 7 days. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg daily for 7 days.
Intervention group: On the first day, patients will receive chloroquine at a doseroutine drug regime (standard of 200 mg, and from the second daycare) daily for six consecutive7 days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg daily for 7 days.
گروه مداخله: روز اول بیماران داروی کلروکین با دوز 200 mg دریافت می کنند و از روز دوم به مدت شش روز متوالی داروی Lopinavir/ritonavir) Kaletra ) با دوز 400/100 mg دریافت خواهند کرد. به افراد این گروه علاوه بر داروهای فوق داروی آلفامد (Tenofovir)، روزانه به میزان 25 mg، به مدت 7 روز داده می شود.
گروه مداخله: از روز اول به مدت 7 روز بیماران routine drug regime (standard of care) دریافت خواهند کرد. به افراد این گروه علاوه بر داروهای فوق داروی آلفامد (Tenofovir)، روزانه به میزان 25 mg، به مدت 7 روز داده می شود.
گروه مداخله: روز اول بیماران داروی کلروکین با دوز 200 mg دریافت می کنند و از روز دوماول به مدت شش7 روز متوالی داروی Lopinavir/ritonavirبیماران routine drug regime (standard of care) Kaletra ) با دوز 400/100 mg دریافت خواهند کرد. به افراد این گروه علاوه بر داروهای فوق داروی آلفامد (Tenofovir)، روزانه به میزان 25 mg، به مدت 7 روز داده می شود.
#2
Control group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg.
Control group: On the first day, patients will receive routine drug regime (standard of care) for 7 days.
Control group: On the first day, patients will receive chloroquine at a doseroutine drug regime (standard of 200 mg, and from the second daycare) for six consecutive7 days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg.
گروه کنترل: روز اول بیماران داروی کلروکین با دوز 200 mg دریافت می کنند و از روز دوم به مدت شش روز متوالی داروی Lopinavir/ritonavir) Kaletra ) با دوز 400/100 mg دریافت خواهند کرد.
گروه کنترل: از روز اول به مدت 7 روز بیماران routine drug regime (standard of care) دریافت خواهند کرد.
گروه کنترل: روز اول بیماران داروی کلروکین با دوز 200 mg دریافت می کنند و از روز دوماول به مدت شش7 روز متوالی داروی Lopinavir/ritonavirبیماران routine drug regime (standard of care) Kaletra ) با دوز 400/100 mg دریافت خواهند کرد.
Recruitment centers
#1
Name of recruitment center - English: Ahvaz Imam khomeini hospital
Name of recruitment center - Persian: بیمارستان امام خمینی اهواز
Full name of responsible person - English: Ali akbar Shayesteh
Full name of responsible person - Persian: علی اکبر شایسته
Street address - English: Khuzestan - Ahvaz - Imam Khomeini Hospital - Alimentary Research Center
Street address - Persian: خوزستان- اهواز- بیمارستان امام خمینی- مرکز تحقیقات گوارش
City - English: Ahvaz
City - Persian: اهواز
Province: Khouzestan
Country: Iran (Islamic Republic of)
Postal code: 6163837194
Phone: +98 61 3333 3333
Fax:
Email: zahrashokati@gmail.com
Web page address:
Name of recruitment center - English: Ahvaz Razi hospital
Name of recruitment center - Persian: بیمارستان رازی اهواز
Full name of responsible person - English: Ali akbar Shayesteh
Full name of responsible person - Persian: علی اکبر شایسته
Street address - English: Khuzestan - Ahvaz - Imam Khomeini Hospital - Alimentary Research Center
Street address - Persian: خوزستان- اهواز- بیمارستان امام خمینی- مرکز تحقیقات گوارش
City - English: Ahvaz
City - Persian: اهواز
Province: Khouzestan
Country: Iran (Islamic Republic of)
Postal code: 6163837194
Phone: +98 61 3333 3333
Fax:
Email: zahrashokati@gmail.com
Web page address:
Name of recruitment center - English: Ahvaz Imam khomeiniRazi hospital Name of recruitment center - Persian: بیمارستان امام خمینیرازی اهواز Full name of responsible person - English: Ali akbar Shayesteh Full name of responsible person - Persian: علی اکبر شایسته Street address - English: Khuzestan - Ahvaz - Imam Khomeini Hospital - Alimentary Research Center Street address - Persian: خوزستان- اهواز- بیمارستان امام خمینی- مرکز تحقیقات گوارش City - English: Ahvaz City - Persian: اهواز Province: Khouzestan Country: Iran (Islamic Republic of) Postal code: 6163837194 Phone: +98 61 3333 3333 Fax: Email: zahrashokati@gmail.com Web page address:
Protocol summary
Study aim
Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients
Design
Clinical trial with control group, parallel group trial, open lable, phase 2 on 60 patients. Replacement randomization was used.
Settings and conduct
In both study groups (control and case), on the first day, patients will receive routine drug regime (standard of care). In addition to the above drugs Alfamed Tenofovir, Case is given daily at 25 mg daily for 7 days.
Participants/Inclusion and exclusion criteria
Inclusion criteria: 1. People over 18 years of age. 2. Positive Real-time PCR test for SARS-CoV-2 virus positive after sampling (nasopharyngeal and oropharyngeal swab samples). 3. Pneumonic manifestations of the virus. In CT scans of the lungs, they should be clearly visible, with a 4% lower O2 Saturation of 93%
exclusion criteria: 1- History of renal failure, 2- Taking drugs that interfere with Tenofovir and 3- Patients who have been included in other clinical trial studies
Intervention groups
Case group: Get the Tenofovir + standard of care
Control group: Get the standard of care
Main outcome variables
Reduce the length of admission time, Reduce the length of ICU admission time, preventing the progression of the disease to acute respiratory distress syndrome (ARDS), Reducing fever, increasing oxygen saturation, Reducing dyspnea, Reducing Respiratory rate, Decreased heart rate.
General information
Reason for update
The standard of care regimens approved by the Ministry of Health differed from the time of the trial at the time of registration. Also, the study method was changed from a double blinding study to an open-label study.
Acronym
Ahvaz TAF study
IRCT registration information
IRCT registration number:IRCT20200422047168N1
Registration date:2020-04-29, 1399/02/10
Registration timing:registered_while_recruiting
Last update:2022-02-19, 1400/11/30
Update count:1
Registration date
2020-04-29, 1399/02/10
Registrant information
Name
Zahra Shokati
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 61 3333 5678
Email address
zahrashokati@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-04-18, 1399/01/30
Expected recruitment end date
2021-01-19, 1399/10/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients
Public title
Clinical trial study on the therapeutic effect of Tenofovir besides routine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
1- People over 18 years of age,
2- Real-time PCR positive test result for SARS-CoV-2 virus was positive after sampling (nasopharynx and oropharynx swab samples).
3. The manifestations of pneumonia caused by the virus in CT scans of their lungs are quite obvious.
4- They have 93% or lower O2 Saturation percentage
Exclusion criteria:
1- History of renal failure,
2- Taking drugs that interfere with Tenofovir
3. Patients who have been admitted to other clinical trials
Age
From 18 years old
Gender
Both
Phase
2-3
Groups that have been masked
No information
Sample size
Target sample size:
60
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, we will use the Restricted randomization method of block randomization. Blockage is usually used to balance the number of samples allocated to each of the studied groups. This feature helps researchers to equalize the number of samples allocated to each of the studied groups in cases where intermediate analyzes are required during the sampling process. All blocks are the same size, and in this two-group experiment we will have 6 blocks (including 3 participants in the intervention group and 3 participants in the control group).
Random allocation software software is also used to randomize random sequence production software (Random allocation software).
To conceal, we use Allocation concealment, which refers to the method used to perform a random sequence on study participants, so that the assigned group is not identified before the individual is assigned. Using non-transparent envelopes sealed with random sequences (Sequentially numbered, sealed, opaque envelopes). They are placed in order. In order to maintain the random sequence, numbering is done on the outer surface of the envelopes in the same way. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants in the study, one of the envelopes of the letter will be opened in order and the assigned group of the participant will be revealed.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Ethics committee of Jundishapur University of Medical Sciences
Street address
Alimentary Tract Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
City
Ahvaz
Province
Khouzestan
Postal code
6163837194
Approval date
2020-04-18, 1399/01/30
Ethics committee reference number
IR.AJUMS.REC.1399.082
Health conditions studied
1
Description of health condition studied
covid-19
ICD-10 code
U07.1
ICD-10 code description
Covid-19, confirmed cases, positive test result
Primary outcomes
1
Description
Reduce the mortality rate of patients with Covid-19
Timepoint
days 0-7
Method of measurement
Based on the percentage of discharged Covid-19 patients
Secondary outcomes
1
Description
Treatment period
Timepoint
0-7
Method of measurement
Based on the days numbers of the drug usage
2
Description
Duration of infection
Timepoint
0-7
Method of measurement
Based on the patient's clinical symptoms
3
Description
Duration of admission time
Timepoint
0-7
Method of measurement
Number of admission days due to Covid-19
4
Description
Duration of ICU admission time
Timepoint
0-7
Method of measurement
Number of ICU admission days due to Covid-19
5
Description
Fever
Timepoint
0-7
Method of measurement
Rising body temperature
6
Description
Blood oxygen saturation percentage
Timepoint
0-7
Method of measurement
O2 saturation percentage
7
Description
Respiratory rate
Timepoint
0-7
Method of measurement
respiratory rate per minute
8
Description
heart rate
Timepoint
0-7
Method of measurement
heart rate per minute
9
Description
Discharge situation
Timepoint
0-7
Method of measurement
Alive or dead
10
Description
Use non-invasive respiratory methods
Timepoint
0-7
Method of measurement
Patients percentage that be supported by non-invasive breathing methods
11
Description
Use invasive respiratory methods
Timepoint
0-7
Method of measurement
Patients percentage that be supported by invasive breathing methods
Intervention groups
1
Description
Intervention group: On the first day, patients will receive routine drug regime (standard of care) daily for 7 days. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg daily for 7 days.
Category
Treatment - Drugs
2
Description
Control group: On the first day, patients will receive routine drug regime (standard of care) for 7 days.
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Ahvaz Razi hospital
Full name of responsible person
Ali akbar Shayesteh
Street address
Khuzestan - Ahvaz - Imam Khomeini Hospital - Alimentary Research Center
City
Ahvaz
Province
Khouzestan
Postal code
6163837194
Phone
+98 61 3333 3333
Email
zahrashokati@gmail.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Mohammad Badavi
Street address
Khuzestan - Ahvaz - Golestan - Ahvaz Jundishapur Medical Sciences
City
Ahvaz
Province
Khouzestan
Postal code
6163837194
Phone
+98 61 3336 2414
Email
iitc@ajums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Ahvaz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Zahra Shokati
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Molecular medicine
Street address
Alimentary Tract Research Center Imam Khomeini Hospital Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran
City
Ahvaz
Province
Khouzestan
Postal code
6163837194
Phone
+98 61 3333 5678
Fax
Email
zahrashokati@gmail.com
Person responsible for scientific inquiries
Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Zahra Shokati
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Molecular medicine
Street address
Alimentary Tract Research Center Imam Khomeini Hospital Ahvaz Jundishapur University of Medical Sciences Ahvaz, Iran
City
Ahvaz
Province
Khouzestan
Postal code
6163837194
Phone
+98 61 3333 5678
Fax
Email
zahrashokati@gmail.com
Person responsible for updating data
Contact
Name of organization / entity
Ahvaz University of Medical Sciences
Full name of responsible person
Ali Akbar Shayesteh
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Gastroenterology
Street address
Imam Khomeini Hospital
City
Ahvaz
Province
Khouzestan
Postal code
6163837194
Phone
+98 61 3333 3333
Email
shayestehaliakbar5@gmail.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available